Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: TIS Clear all
Completed Phase 3 Interventional

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

NCT00000748
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
24
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 7, 2026, 1:31 PM EDT
Active, not recruiting Phase 2 Interventional

Intrapleural Catheter Daily Versus Three Times a Week Drainage

NCT00761618
View directory record Official record
Conditions
Advanced Cancer, Pleural Effusion
Interventions
Intrapleural catheter (IPC) drained, IPC Placement, Chest X-Ray
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

NCT00001028
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

NCT00943995
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Dialysis
Interventions
somatropin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116662
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Newnan, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Glatiramer Acetate

NCT01874145
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
GA 20 mg/mL, GA 40 mg/mL
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

NCT00551850
View directory record Official record
Conditions
Advanced Cancer, Refractory Cancer
Interventions
AV-412
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 7, 2026, 1:31 PM EDT
Completed No phase listed Observational

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

NCT03284970
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ertapenem
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 88 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 7, 2026, 1:31 PM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Glatiramer acetate (GA), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT06901505
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00089154
View directory record Official record
Conditions
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
apolizumab, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

NCT00530348
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab, Interferon beta-1a
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
36
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

NCT00023283
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 7, 2026, 1:31 PM EDT
Completed No phase listed Observational

Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome

NCT02241954
View directory record Official record
Conditions
Thoracic Insufficiency Syndrome (TIS)
Interventions
Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 7, 2026, 1:31 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Temporal Interference Stimulation for Social Cognition

NCT06607432
View directory record Official record
Conditions
Healthy Controls
Interventions
Transcranial Interference Stimulation (tIS), Sham tIS
Device · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086
View directory record Official record
Conditions
Lymphoma
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 7, 2026, 1:31 PM EDT